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Cadmium (Cd), a ubiquitous toxic element 
and widespread pollutant, is introduced to 
the environment mainly through anthropo­
genic activities, such as lead mining, fos­
sil fuel combustion, and the manufacturing 
of Cd­containing products. Another major 
source for human exposure to Cd is cigarette 
smoke (Martelli et al. 2006). The chief route 
of Cd exposure is via the respiratory system 
(Potts et al. 2001).
Because of its stability in the environment 
and long retention time in the human body 
(half­life, ~ 20 years), Cd can accumulate 
and cause a variety of adverse effects (Joseph 
2009; Waalkes 2003). The target organs for 
Cd toxicity include the liver, kidney, lung, 
testis, prostate, and bladder. However, pro­
longed human exposure to Cd results mainly 
in diseases affecting lungs and kidneys 
[International Agency for Research on Cancer 
(IARC) 1993]. Cd has been classified as a 
class 1 human carcino  gen by IARC (1993). 
Most of our current knowledge regarding the 
mechanisms of Cd carcino  genesis is derived 
from experi  ments conducted with cell cul­
tures and animal models. These studies have 
shown that the mechanisms underlying Cd 
carcinogenesis are multi  factorial (Huff et al. 
2007). Among these mechanisms, accumula­
tion of DNA damage due to inhibition of 
DNA repair enzymes by Cd is considered as 
one of the major underlying processes (Jin 
et al. 2003; McNeill et al. 2004; Potts et al. 
2001). Simultaneous and/or sequential expo­
sure to Cd has been suggested to contribute to 
the carcinogenic potential of other geno  toxic 
chemicals commonly found in the environ­
ment and in the workplace, such as aromatic 
carcinogens (Prakash et al. 2000; Rivedal and 
Sanner 1981; Williams et al. 1984).
Aromatic amines (AAs) represent one of 
the most important classes of occupational 
or environmental pollutants (Kim and 
Guengerich 2005). AAs account for 12% of 
the chemicals known or strongly suspected 
to be carcinogenic in humans (National 
Toxicology Program 2005). AAs are by­ 
products of chemical manufacturing (e.g., 
pesticides, dyestuff, rubbers), gasoline com­
bustion, or pyrolysis reactions (Palmiotto et al. 
2001). Carcinogenic AAs such as 4­aminobi­
phenyl (4­ABP) and β­naphthylamine are also 
present in cigarette smoke (Hein 1988; Hein 
et al. 2000). 
Human arylamine N­acetyltransferases 
(NATs) are xeno  biotic­metabolizing enzymes 
(XMEs) that play a major role in the bio­
transformation of AA carcinogens (Dupret and 
Rodrigues­Lima 2005; Hein 1988). The inter­
relationship between variable NAT activities 
and the toxicity or carcino  genicity of environ­
mental AAs has been reported (Badawi et al. 
1995; Gemignani et al. 2007; Hein 1988; 
Minchin et al. 1993). NAT­dependent acetyla­
tion of AAs leads mainly to xeno  biotic detoxi­
cation but also to bio  activation. Detoxification 
into innocuous compounds is mainly medi­
ated by NAT­dependent N­acetylation, whereas 
O­acetylation of chemi  cals previously hydroxy­
lated by cytochrome P450 1A1 (CYP1A1) or 
CYP1A2 promotes their metabolic activation 
into DNA­binding electrophiles (Hein 1988). 
Several studies have shown associations between 
NAT1 and/or NAT2 activities and increased 
risk of cancer, particularly in relation with expo­
sures to AAs (Hein 1988; Hein et al. 2000). 
Exposure to both Cd and AAs occurs 
commonly, such as through cigarette smoke 
(Joseph 2009; Stavrides 2006). Although 
Cd has been shown to modify the expres­
sion and/or activity of CYP1A1 (Elbekai 
and El­Kadi 2007; Vakharia et al. 2001), the 
effect of this metal on the metabolism of aro­
matic carcinogens remains poorly defined. In 
this study, we found molecular, cellular, and 
in vivo evidence that Cd, at biologically rele­
vant concentrations, can alter the biotrans­
formation of AA carcinogens through the 
impairment of the NAT­dependent acetyla­
tion pathway. This process may represent an 
additional mechanism contributing to Cd 
  carcinogenesis.
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Ba c k g r o u n d: Cadmium (Cd) is a carcinogenic heavy metal of environmental concern. Exposure to 
both Cd and carcinogenic organic compounds, such as polycyclic aromatic hydrocarbons or aromatic 
amines (AAs), is a common environmental problem. Human arylamine N-acetyltransferases (NATs) 
are xenobiotic-metabolizing enzymes that play a key role in the biotransformation of AA carcino-
gens. Changes in NAT activity have long been associated with variations in susceptibility to different 
  cancers in relation with exposure to certain AAs.
oB j e c t i v e: We explored the possible interactions between Cd and the NAT-dependent biotrans-
formation of carcinogenic AAs.
Me t h o d s : We exposed purified enzymes, lung epithelial cells, and mouse models to Cd and 
  subsequently analyzed NAT-dependent metabolism of AAs. 
re s u l t s: We found that Cd, at biologically relevant concentrations, impairs the NAT-dependent 
acetylation of carcinogenic AAs such as 2-aminofluorene (2-AF) in lung epithelial cells. NAT activ-
ity was strongly impaired in the tissues of mice exposed to Cd. Accordingly, mice exposed to Cd 
and 2-AF displayed altered in vivo toxico  kinetics with a significant decrease (~ 50%) in acetylated 
2-AF in plasma. We found that human NAT1 was rapidly and irreversibly inhibited by Cd [median 
inhibitory concentration (IC50) ≈ 55 nM; rate inhibition constant (kinact) = 5 × 104 M–1 • sec–1], 
with results of acetyl coenzyme A (acetyl-CoA) protection assays indicating that Cd-mediated inhi-
bition was due to the reaction of metal with the active-site cysteine residue of the enzyme. We found 
similar results for human NAT2, although this isoform was less sensitive to inactivation (IC50 ≈ 
1 μM; kinact = 1 × 104 M–1 • sec–1).
co n c l u s i o n s: Our data suggest that Cd can alter the metabolism of carcinogenic AAs through the 
impairment of the NAT-dependent pathway, which may have important toxicological consequences.
key w o r d s : aromatic amine carcinogens, arylamine N-acetyltransferases, cadmium, irreversible 
inhibition, xenobiotic metabolism. Environ Health Perspect 118:1685–1691 (2010).  doi:10.1289/
ehp.1002334 [Online 1 September 2010]Ragunathan et al.
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Materials and Methods
Materials. Cadmium chloride (CdCl2), 
2­aminofluorene (2­AF), 4­ABP, acetyl coen­
zyme A (acetyl­CoA), coenzyme A (CoA), 
and protease inhibitors were obtained from 
Sigma (St­Quentin Fallavier, France). Cell 
culture reagents were from Invitrogen (Cergy, 
France). All other reagents were purchased 
from Euromedex (Soufferweyersheim, France) 
unless otherwise stated.
Recombinant enzyme production and 
purification. Hexa­histidine (6xHis)­tagged 
human NAT1 was produced and purified 
from Escherichia coli strain BL21 (DE3) as 
previously described (Dairou et al. 2003). We 
used the same approach to prepare human 
NAT2, except that induction with iso  propyl 
β­d­1­thiogalactopyranoside (500 μM) was 
performed at 30°C for 8 hr followed by 
a 12­hr incubation at 4°C.
Effects of Cd on recombinant human 
NAT enzymes. We tested the effect of Cd on 
recombinant human NAT1 and NAT2 by 
incubating purified enzymes (0.3 μM final 
concentration) with increasing concentra­
tions of CdCl2 in 25 mM Tris­HCl (pH 7.5) 
for 10 min at 37°C. Recombinant NAT1 or 
NAT2 enzymatic activities were determined 
spectrophotometrically using p­nitro  phenyl­
acetate (PNPA) as the acetyl donor and 2­AF 
as arylamine substrate, as reported previously 
(Dairou et al. 2003; Mushtaq et al. 2002). In 
all reaction mixtures, the final concentrations 
of NAT1 and NAT2 were 15 nM and 30 nM, 
respectively. For the controls, we omitted the 
enzyme, 2­aminofluorene (2­AF), or PNPA. 
All enzyme reactions were performed in tripli­
cate, in conditions in which the initial reaction 
rates were linear.
We assessed the reversibility of the reac­
tion of Cd with NAT1 and NAT2 by incu­
bating recombinant enzymes with Cd (final 
concentrations, 0.3 μM for NAT1 and 2 μM 
for NAT2) for 10 min at 37°C. Mixtures were 
then dialyzed overnight at 4°C against 25 mM 
Tris­HCl, pH 7.5. For controls, enzymes not 
treated with Cd were dialyzed overnight. After 
dialysis, residual enzyme activities were assayed.
We tested whether reducing agents 
[reduced glutathione (GSH) and dithio  threitol 
(DTT)] or the chelating agent EDTA was able 
to restore the activity of Cd­inhibited NAT1 
and NAT2. To this end, recombinant enzymes 
were pre  incubated with Cd (final concentra­
tions, 0.3 μM in experiments with NAT1 
and 2 μM in those with NAT2) for 10 min 
at 37°C. Mixtures were then incubated with 
different concentrations of DTT or GSH (up 
to 10 mM final concentration) or EDTA (up 
to 5 mM final concentration) for 10 min at 
37°C. Residual enzyme activities were then 
assessed. Control assays were carried out as 
described above in the absence of Cd but with 
GSH, DTT, or EDTA. We also tested whether 
these reducing or chelating agents were able 
to protect NAT1 and NAT2 enzymes from 
the inhibitory effects of Cd by carrying out 
Cd treatments (final concentration, 0.3 μM 
in experiments with NAT1 and 2 μM in those 
with NAT2) in the presence of high concentra­
tions of DTT, GSH, or EDTA (up to 10 mM, 
which corresponds to > 33,000 times the Cd 
concentration) and then determining residual 
enzyme activities. 
We investigated the extent to which 
acetyl­CoA and CoA protected NAT1 and 
NAT2 from Cd­dependent inhibition. To this 
end, recombinant enzymes were preincubated 
with different concentrations of acetyl­CoA 
or CoA in 25 mM Tris­HCl, pH 7.5, for 
5 min at 37°C. Mixtures were then incu­
bated with Cd (final concentration, 0.3 μM 
for NAT1 experiments and 2 μM for NAT2 
experiments) for 10 min at 37°C (final con­
centration of acetyl­CoA or CoA, 0–3 mM). 
Samples were then assayed. Control assays 
carried out in the absence of Cd treatment 
gave 100% enzyme activity.
Kinetic analysis: determination of the 
second-order rate inhibition constant (kinact). 
NAT1 or NAT2 was incubated under second­
order conditions as described previously by 
Cornish­Bowden (2001). Briefly, recombinant 
enzymes (0.3 μM final concentration) were 
incubated with Cd (0.3 μM final concentra­
tion) in 25 mM Tris­HCl, pH 7.5, at 37°C. 
Every 2 min, aliquots of the reaction mixture 
were taken and quenched by dilution with buf­
fer containing 1 mM EDTA, and the residual 
enzyme activity was assayed as described below. 
The values of kinact were obtained by fitting 
residual enzyme activity to the equation 
 1 /E = 1/E0 + (kinact × t), 
where E is the enzyme concentration, E0 is 
the initial enzyme concentration, and t is 
time. We used KaleidaGraph, version 3.5 
(Abelbeck/Synergy, Reading, PA, USA) for 
mathematical analyses of the data.
Cell culture, exposure to Cd, and whole-
cell extracts. The murine mtCC1­2 Clara lung 
epithelial cell line (Magdaleno et al. 1997) was 
provided by J.M. Sallenave (Institut Pasteur, 
Paris, France) and grown in Dulbecco’s modi­
fied Eagle’s medium (DMEM) supplemented 
with 20% (vol/vol) fetal bovine serum. Cells 
were cultured as mono  layers in 35­ or 100­mm 
Petri dishes at 37°C. This lung epithelial 
cell line is known to express only functional 
Nat2 (the murine ortholog of human NAT1) 
(Dairou et al. 2009).
Cell monolayers (~ 80% confluence) were 
washed with phosphate­buffered saline (PBS) 
and exposed to different concentrations of 
CdCl2 in 10 mL PBS or DMEM for 2 hr at 
37°C in a cell incubator. Control cells were 
incubated with PBS or DMEM only. After 
incubations, mono  layers were washed with 
PBS and scraped into 0.5–1 mL lysis buf­
fer (25 mM Tris­HCl, pH 7.5; 0.1% Triton 
X­100) and protease inhibitors. Extracts 
were sonicated and centrifuged for 15 min at 
13,000 × g. Supernatants (whole­cell extracts) 
were removed, and their protein concentra­
tion was determined using Bradford reagent 
with bovine serum albumin as a standard. All 
cell extracts were adjusted to the same pro­
tein concentration by adding lysis buffer and 
were used for enzyme assays. We determined 
NAT activity in cells or mouse tissue extracts 
by measuring the formation of N­acetylated 
Figure 1. Inhibition of human NAT1 by CdCl2. Residual activity after preincubation of NAT1 with increas-
ing concentrations of CdCl2 for 10 min at 37°C. Inset: semilogarithm plot of data. Data are presented as 
mean ± SD as a percentage of control of experiments performed in triplicate, with NAT1 activity deter-
mined in triplicate.
*p < 0.05 compared with NAT1 activity in the control.
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metabolites using reverse­phase high­
  performance liquid chromatography (HPLC) 
as described previously (Grant et al. 1991). 
All assays were performed in triplicate under 
initial reaction rate conditions. Enzyme activi­
ties were normalized according to the protein 
concentration of cellular extracts determined 
using the Bio­Rad protein assay kit (Bio­Rad, 
Hercules, CA, USA).
We analyzed CdCl2 cytotoxicity using a 
3­(4,5­dimethyl  thiazol­2­yl)­2,5­diphenyl­
tetrazolium bromide (MTT)­based assay 
(Mosmann 1983) with concentrations of 
CdCl2 ranging from 0 to 100 μM. In the 
conditions used above, CdCl2 cytotoxicity 
was < 5% for concentrations up to 50 μM.
Acetylation of AA carcinogens by intact cul-
tured cells in the presence or absence of Cd. 
Acetylation of 2­AF and 4­ABP by endoge­
nous Nat2 in growing cells was measured by 
reverse­phase HPLC as described previously 
(Wu et al. 2000). Cells were incubated with 
Cd at different concentrations (up to 50 μM) 
for 2 hr. After treatment, cells were grown in 
fresh culture medium containing 750 μM 
2­AF or 4­ABP. Controls were incubated in 
the same conditions but with cell monolayers 
not exposed to Cd. Reactions were found to be 
linear with time.
In a second set of experiments, Clara cells 
were coexposed to Cd at different concentra­
tions (up to 50 μM final) and to 750 μM 
2­AF (or 4­ABP) in culture medium. At dif­
ferent time points, aliquots were analyzed as 
described above.
Mouse Cd exposure and plasma pharmaco-
kinetics. All procedures involving animals were 
carried out in accordance with the French 
Agriculture Ministry’s internal guidelines for 
animal handling. The number of mice and 
suffering were minimized whenever possible. 
We investigated the ability of Cd to 
inhibit NAT functions in vivo by treating 
12­week­old female C57BL/6J mice with a 
sub  lethal dose of CdCl2 (2 mg/kg in PBS), 
as reported previously (Martin et al. 2007). 
Two hours after intra  peritoneal (IP) injection, 
mice (n = 7) were sacrificed by cervical dis­
location, and endogenous NAT activity was 
measured in protein lysates of tissues known 
to be targeted by Cd, such as blood, liver, kid­
ney, and lung. Tissue extracts were prepared as 
described previously (Smelt et al. 2000).
In a second set of experiments, we ana­
lyzed the in vivo pharmaco  kinetics of acety­
lated 2­AF in mice (n = 7) with or without 
CdCl2 treatment (2 mg/kg in PBS). Two 
hours after Cd treatment, 2­AF (50 mg/kg) 
dissolved in dimethyl sulfoxide was adminis­
tered by IP injection. Animals were then 
anesthetized with 10 mg/kg ketamine and 
1 mg/kg xylazine, and blood samples were 
drawn from retro­orbital venous plexus at five 
sequential time points (30 min, 1 hr, 2 hr, 
3 hr, and 6 hr). Samples were diluted 1:50 
in HPLC mobile phase and analyzed for par­
ent and acetylated metabolites by HPLC as 
described above. Area under the curve (AUC) 
was determined by the trapezoidal rule using 
Microsoft Excel 2007 (Microsoft Corporation, 
Paris, France). 
Statistical analysis. Data are presented as 
mean ± SD of three independent experiments 
performed in triplicate, unless otherwise stated. 
One­way analysis of variance was performed, 
followed by Student’s t­test between two groups 
using StatView 5.0 (SAS Institute Inc., Cary, 
NC, USA).
Results
Cd impairs recombinant human NAT1 and 
NAT2 activity. To test whether Cd can inhibit 
human NAT1 and NAT2 activity, we assessed 
its effect on purified recombinant enzymes. 
As shown in Figure 1, Cd demon  strated a 
dose­dependent inhibitory effect on NAT1 
activity. Full inhibition of NAT1 was obtained 
with Cd concentrations as low as 0.3 μM. The 
median inhibitory concentration (IC50) for Cd 
was approxi  mately 0.055 μM (Figure 1, inset). 
We also observed dose­dependent inhibition 
of the human NAT2 isoform by Cd (data 
not shown) but with a higher IC50 (~ 1 μM). 
These data indicate that both human NAT 
isoforms are readily inhibited in vitro by low, 
biologically relevant concentrations of Cd.
Inhibition of human NAT enzymes by Cd 
is rapid and irreversible. We tested whether the 
inhibition of NAT1 by Cd could be reversed 
by physiological (GSH) and non  physiological 
(DTT) reducing agents that are known to 
react with Cd. DTT and GSH (1–10 mM 
final concentrations) did not significantly 
reverse Cd­dependent inhibition of NAT1 
(Figure 2A). We observed a modest reactivation 
effect (~ 20% of control activity) with high 
concentrations of DTT or GSH (10 mM final 
concentration). Similar results were obtained 
for human NAT2 (data not shown).
We also tested whether EDTA, a known 
Cd­chelating agent, was able to reverse 
Cd­dependent inhibition of NAT1 and NAT2. 
Incubation of inhibited enzymes with differ­
ent concentrations of EDTA for 30 min at 
37°C did not reverse the inhibitory effect of Cd 
(Figure 2A). To further analyze the irreversible 
Figure 2. Scavenging effects of GSH and DTT toward Cd-dependent inhibition of NAT1. NAT1 was pre-
incubated with 0.3 μM CdCl2 for 10 min at 37°C before (A) or in the presence of (B) different concentrations 
of GSH, DTT, or EDTA. The data are mean ± SD of experiments done in triplicate, with NAT1 activity deter-
mined in triplicate.
*p < 0.05 compared with NAT1 activity in controls. #p < 0.05 compared with Cd-inhibited NAT1.
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reaction of Cd with human NAT enzymes, 
we carried out dialysis experiments. In agree­
ment with the results reported above, dialysis 
of Cd­inhibited NAT1 and NAT2 enzymes did 
not allow any significant recovery of enzymatic 
activity (data not shown). Taken together, these 
results indicate that Cd­dependent inhibition 
of NAT enzymes is irreversible.
In a second set of experiments, we ana­
lyzed the ability of DTT and GSH to pre­
vent Cd­dependent inhibition of NAT1. 
Incubation of the enzyme with Cd in the pres­
ence of these compounds at high concentra­
tions (> 33,000 times the Cd concentration) 
protected NAT1 only partially against inhi­
bition (Figure 2B). At high final concentra­
tions of 10 mM GSH or DTT, we observed 
approximately 60% residual NAT1 activity. 
Similar results were obtained for NAT2 (data 
not shown). These data indicate that reducing 
agents, even at high concentrations, provide 
only partial protection against Cd­dependent 
inhibition of NAT enzymes, suggesting that 
Cd reacts more quickly with NAT enzymes 
than with GSH or DTT. Conversely, EDTA 
(2 mM final concentration) provided almost 
full protection (~ 85%), indicating the depen­
dence of inhibition on the presence of free 
metal ions in solution (Figure 2B).
To further characterize the reaction of Cd 
with NAT enzymes, we performed kinetic 
analy  ses. Pseudo­first­order conditions (i.e., 
implying Cd concentrations were well above 
enzyme concentration) could not be used 
because the enzymes were almost instantly 
inhibited by Cd under these conditions. 
Therefore, we used second­order conditions 
(see “Materials and Methods”) to determine the 
second­order rate constant of inhibition (kinact). 
The kinact constant for Cd­dependent inhibition 
of NAT1 was 5.2 × 104 M–1 • s–1 (Figure 3, 
inset). The kinact for NAT2 was slightly lower 
(1 × 104 M–1 • s–1). These results confirm the 
high reactivity of Cd toward NAT1 and NAT2 
enzymes in vitro.
Cd-dependent inhibition is due to inter-
action with the active-site cysteine residue of 
NAT enzymes. Alteration of cellular func­
tions by binding to certain thiol groups of 
bio  molecules is the most commonly invoked 
pathway for Cd toxicity (Joseph 2009). To 
investigate whether the Cd­dependent inhibi­
tion of these XMEs could be due to direct 
reaction of Cd with the active­site cysteine 
residue of NAT enzymes, we carried out sub­
strate protection assays using acetyl­CoA and 
CoA as reported previously (Liu et al. 2008). 
This protection assay relies on the specific 
acetylation of the NAT active­site cysteine 
residue by acetyl­CoA, which protects this 
residue from further chemical reaction (Liu 
et al. 2008). Conversely, because CoA is 
unable to acetylate the active­site cysteine 
residue, this amino acid is thus suscepti­
ble to chemical reaction in the presence of 
CoA. Acetyl­CoA afforded significant dose­
  dependent protection against Cd­dependent 
NAT1 inhibition (up to 70% residual NAT1 
activity; Figure 4). In contrast, CoA did not 
provide any significant protection against 
Cd­dependent inhibition. We observed 
similar results with the NAT2 isoform (data 
not shown). These data suggest that in vitro, 
Cd irreversibly inhibits NAT1 and NAT2 
enzymes through the direct interaction with 
their active­site cysteine residues.
Impairment of the endogenous NAT-
dependent biotransformation pathway in 
lung epithelial Clara cells by Cd. We tested 
the effect of Cd on endogenous NAT activ­
ity by measuring acetylated metabolites of 
2­AF and 4­ABP in the culture medium of 
mtCC1­2 Clara cells not exposed or previ­
ously exposed to different concentrations of 
Cd. Clara cells are known to play a major role 
in lung xeno  biotic metabolism and are the 
progenitor cells for broncho  genic carcinomas 
(Oreffo et al. 1990). Recently, Clara cells were 
shown to biotransform AA chemicals through 
the Nat2­dependent pathway (Dairou et al. 
2009). We exposed mtCC1­2 Clara cells 
[which express only Nat2, the murine coun­
terpart of human NAT1 (Kawamura et al. 
2008)] to Cd for 2 hr and then to 2­AF or 
4­ABP (in fresh medium with no Cd). We 
observed that the amount of acetylated 2­AF 
and 4­ABP in cell culture medium decreased 
in a dose­dependent manner with an IC50 
value for CD around 17 μM (Figure 5A). We 
observed similar results in cells co  exposed to 
Cd and AAs (data not shown). Moreover, 
these results are in agreement with enzyme 
assays carried out with extracts of treated 
mtCC1­2 cells (Figure 5B). Overall, these 
data indicate that exposure to Cd alters the 
acetylation of AAs in lung epithelial Clara 
cells through impairment of the endogenous 
NAT­dependent pathway.
Effect of Cd on the in vivo NAT-dependent 
biotransformation of 2-AF. In C57BL/6J mice 
(n = 7) treated with a sub  lethal dose of CdCl2 
(2 mg/kg) as described previously (Martin 
et al. 2007), we found that Cd to significantly 
decreased NAT activity in the lungs, kidneys, 
liver, and blood of treated mice (up to 52% 
inhibition in the lung; Figure 6A). These data 
were further confirmed by plasma toxico­
kinetics experiments with 2­AF, which showed 
that Cd­treated mice exhibited altered levels 
of N­acetylated 2­AF with an approximately 
50% decrease in the AUC (mean ± SD, 
1.43 ± 0.15 mmol­min/L for control mice 
and 0.81 ± 0.12 mmol­min/L for treated 
mice; Figure 6B). Taken together, these data 
indicate that Cd alters the NAT­dependent 
acetylation of 2­AF in vivo.
Figure 3. Determination of kinact for inhibition of NAT1 by Cd under second-order 
conditions. After equimolar concentrations of NAT1 and CdCl2 were incubated, 
residual NAT1 activity was assayed at 2-min intervals. Inset: kinact obtained by 
fitting the data to the equation 1/E = 1/E 0 + kinact × t and taking kinact from the 
slope of 1/E versus time. 
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Figure 4. Effect of acetyl-CoA on the Cd-dependent inhibition of NAT1. NAT1 
(0.3 μM) was incubated with CdCl2 (0.3 μM) in the presence of different con-
centrations of acetyl-CoA or CoA, and NAT1 activity was determined. The 
data are mean ± SD of experiments done in triplicate, with NAT1 activity was 
determined in triplicate. 
*p < 0.05 compared with Cd-inhibited NAT1.
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Discussion
The cellular effects of the toxic metal Cd are 
manifold. In particular, exposure to Cd is asso­
ciated with cancers of the prostate, bladder, 
kidney, and lung (Huff et al. 2007; Waalkes 
2003). Because Cd interacts with cellular 
components in many ways, no factor fully 
accounts for its spectrum of toxic and carci­
nogenic effects (Joseph 2009). Several stud­
ies have demonstrated that Cd is a complex 
carcinogen, and the mechanisms underlying 
Cd carcino  genesis are multifactorial (reviewed 
by Joseph 2009). Cd interacts synergistically 
with DNA­damaging agents, such as aromatic 
carcinogens, which may enhance their muta­
genic potential and result in biologically rele­
vant genotoxic effects (Godschalk et al. 2005; 
Prakash et al. 2000; Rivedal and Sanner 1981; 
Williams et al. 1984). Although Cd has been 
suggested to modify the expression of certain 
XMEs such as CYP1A1 (Elbekai and El­Kadi 
2007; Maier et al. 2000), the potential of Cd 
to alter the biotransformation of aromatic 
carcino  gens remains poorly defined.
NATs are XMEs that play a major role in 
the biotransformation of AA carcinogens, and 
changes in the N­ and/or O­acetylation of 
these chemicals have been linked to carcino­
genesis (Hein 1988). We report here that 
biologically relevant levels of Cd (≤ 50 μM) 
(Apostolova et al. 2006) alter the biotransfor­
mation of carcinogenic AAs through impair­
ment of NAT enzyme functions. We found 
that Cd can irreversibly inhibit NAT1 and 
NAT2 acetylation activities in vitro with IC50 
values as low as 75 nM and 1 μM, respec­
tively. Kinetic analysis of these Cd­dependent 
inhibitions gave second­order kinact values 
of 5 × 104 M–1 • s–1 and 1 × 104 M–1 • s–1 
for human NAT1 and NAT2, respectively. 
Studies on DNA repair enzymes known to 
be impaired by Cd, such as Ogg1 and poly­
nucleotide kinase, have reported IC50 values 
ranging from 5 to 100 μM (Bravard et al. 
2006; McNeill et al. 2004; Whiteside et al. 
2010; Zharkov and Rosenquist 2002) and 
kinact values around 5 M–1 • s–1 (Zharkov and 
Rosenquist 2002). The data we obtained for 
NAT enzymes indicate that these XMEs are 
extremely sensitive to Cd exposure, which 
leads to their rapid functional impairment. 
Moreover, our results suggest that in vitro, 
NAT1 is more susceptible to Cd­dependent 
inhibition than is NAT2. A similar trend with 
isoform­selective inactivation of human NAT 
enzymes by 4­nitrosobiphenyl and 2­nitroso­
fluorene was recently reported, with NAT1 
appearing to be more sensitive to these com­
pounds (Liu et al. 2009).
Cd has been reported to act as either a 
reversible or an irreversible inhibitor of cer­
tain enzymes, depending on the nature of 
the enzyme–Cd interaction. For instance, 
Whiteside et al. (2010) have shown that 
different DNA repair enzymes exhibit differ­
ent behaviors in this regard. In the present 
study, we found that the in vitro inhibition 
of NAT1 and NAT2 by Cd was irreversible 
because extensive dialysis did not restore 
enzyme activities. Moreover, the reduc­
ing agents GSH or DTT and the chelating 
agent EDTA did not restore the activity of 
NAT1 and NAT2, further supporting the 
irreversible nature of the Cd­dependent inhi­
bition of these XMEs. We also found that 
the presence of high concentrations of GSH 
or DTT (10 mM final) afforded only partial 
protection (~ 60% residual activity) against 
Cd­dependent inhibition (with Cd at a molar 
concentration > 33,000 times lower than 
that of GSH or DTT). These data suggest 
that Cd reacts more rapidly with NAT1 (and 
NAT2) than with GSH or DTT. Accordingly, 
the kinetics of the Cd reaction with GSH 
is at least two orders of magnitude lower 
(kassoc < 102 M–1 • s–1) than the inactiva­
tion rates found for NAT1 and NAT2 (kinact 
> 104 M–1 • s–1). Conversely, we found that 
EDTA afforded significant protection against 
Cd­dependent inhibition of human NAT 
enzymes. These results are similar to data 
obtained with the DNA repair enzyme Ogg1 
and indicate the dependence of inhibition 
on the presence of free metal ions in solution 
(Zharkov and Rosenquist 2002). Acetyl­CoA 
protection assays indicated that Cd­dependent 
irreversible inhibition of human NAT1 and 
NAT2 was due to the reaction of the metal 
with the reactive catalytic cysteine residue 
(Ragunathan et al. 2008), which is in agree­
ment with the fact that Cd exhibits high affin­
ity for certain reactive thiols (Bravard et al. 
2006). A similar mechanism of inhibition has 
been reported for other enzymes inhibited by 
Cd, such as Ogg1 and nicotinamide adenine 
dinucleotide phosphate–dependent isocitrate 
dehydrogenase (Kil et al. 2006).
The amount of Cd absorbed in the body 
after exposure is principally due to inhala­
tion of Cd­contaminated smoke and parti­
cles and results mainly in diseases affecting 
kidneys and lungs (Joseph 2009). Cd has 
been shown to accumulate in tissues at up 
to tens­of­micromolar concentrations (Jin 
et al. 2003). Furthermore, occupational expo­
sures in industrial society have been reported 
to produce renal cortical Cd concentrations 
around 300 μM (Apostolova et al. 2006). 
We exposed murine Clara cells, which are 
known to express functional Nat2, the murine 
Figure 5. Inhibition of endogenous Nat2 activity and AA acetylation in Clara cells by Cd. Cells in Petri 
dishes were exposed to different concentrations of CdCl2 for 2 hr and then grown in fresh culture medium 
in the presence of 750 μM 2-AF or 4-ABP. (A) The amount of acetylated 2-AF or acetylated 4-ABP quanti-
tated (in triplicate) in culture medium by HPLC. (B) Cells were washed, and a whole-cell extract was made; 
Nat2 activity was measured by HPLC in normalized extracts using 2-AF as substrate. Data are mean ± SD. 
*p < 0.05. 
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Figure 6. Impairment of Nat2 activity in tissues of mice exposed to Cd (A) and pharmacokinetics of acety-
lated 2-AF (B). CdCl2 (2 mg/kg) was injected IP. Adult C57BL/6J mice (n = 7) were injected IP with 2 mg/kg 
CdCl2. (A) Two hours after injection, mice were sacrificed, and Nat2 activity was assessed in lysates from 
the liver, kidney, lung, and blood. (B) Two hours after CdCl2 injection, 2-AF (50 mg/kg) dissolved in dimethyl 
sulfoxide was administered by IP injection, and acetylated 2-AF was measured in blood at different time 
points. Acetylated 2-AF AUC values: untreated, 1.43 ± 0.15 mmol-min/L; Cd treated, 0.81 ± 0.12 mmol-min/L. 
Data are mean ± SD. 
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ortholog of human NAT1 (Kawamura et al. 
2008; Minchin et al. 2007), to biologically 
relevant concentrations of Cd (≤ 50 μM). We 
found that Cd impaired the NAT­dependent 
biotransformation of two carcinogenic AAs 
(4­ABP and 2­AF) through inhibition of the 
endogenous Nat2 enzyme with an IC50 close 
to 20 μM. Similar IC50 values have been 
reported for enzymes such as caspase 3 (Yuan 
et al. 2000) and apurinic/apyrimidic endonu­
clease 1 (McNeill et al. 2004) inhibited by Cd 
in cultured mammalian cells. Moreover, expo­
sure of lung alveolar epithelial cells to Cd has 
been shown to significantly reduce the activ­
ity of the DNA repair enzyme formamido­
pyrimidine DNA glycosylase (Potts et al. 
2001). Our results are also in agreement with 
previous data showing that the acetylation 
of 3­chloroaniline in isolated rat hepatocytes 
could be suppressed by Cd concentrations 
close to 25 μM (Alary et al. 1989).
Cd significantly inhibited (by 36–52%) 
endogenous NAT activity in lung, liver, kid­
ney, and blood, tissues known to accumulate 
Cd (Huff et al. 2007; Joseph 2009), from 
mice exposed to Cd IP. These data indicate 
that NAT­dependent biotransformation of 
AAs may be altered by Cd in several tissues 
expressing these XMEs. Toxicokinetics stud­
ies provided further evidence that in vivo Cd 
alters the NAT­dependent biotransformation 
of carcinogenic AAs. Mice exposed to Cd 
exhibited altered biotransformation of 2­AF, 
as shown by the 50% decrease in acetylated 
2­AF AUC. 
Increasing evidence suggests that geno­
toxicity induced by Cd also depends on the 
synergic interactions of Cd with genotoxic 
chemicals (Joseph 2009). Cd inhibits several 
enzymes involved in DNA repair, and this 
has been identified as a major mechanism 
underlying the carcinogenic potential of Cd 
(Joseph 2009; Zharkov and Rosenquist 2002). 
Furthermore, synergic interactions between 
Cd and carcinogenic aromatic chemi  cals that 
can lead to aromatic DNA adducts have been 
reported (Godschalk et al. 2005; Prakash et al. 
2000; Rivedal and Sanner 1981; Williams 
et al. 1984). Moreover, studies have shown 
that Cd can modify the expression and/or 
activity of certain XMEs, such as CYP1A1, 
leading to altered metabolism of polycyclic 
aromatic hydrocarbons such as benzo[a]pyrene 
(Elbekai and El­Kadi 2007; Maier et al. 2000; 
Vakharia et al. 2001). Interestingly, Cd has 
been proposed to enhance mutagenicity of 
benzo[a]pyrene metabolites (Prakash et al. 
2000).
Cd toxicity is caused by both acute and 
chronic exposure. Although the toxicity of Cd 
is considered mostly chronic, several studies 
using acute conditions have yielded a substantial 
amount of information pertinent to Cd toxic­
ity, including mechanistic information (Bravard 
et al. 2006; McNeill et al. 2004). Moreover, 
acute inhalation of high levels of Cd in humans 
may result in long­lasting impairment of lung 
functions (Agency for Toxic Substances and 
Disease Registry 1997). Here, we showed that 
acute exposure to Cd alters the biotransforma­
tion of AAs in several tissues, including lung. 
Further studies are needed to assess whether 
chronic exposure to Cd leads to similar effects.
Humans are exposed to AA carcinogens 
mainly through cigarette smoke or occupa­
tional/industrial pollutants. Several studies 
have suggested that NAT­dependent acetyla­
tion is a susceptibility factor for cancers associ­
ated with AA exposures (Hein 1988), possibly 
through formation of aromatic DNA adducts 
(Badawi et al. 1995). Interestingly, simulta­
neous and/or sequential exposure to Cd and 
AAs occurs commonly, such as in cigarette 
smoke (Hein et al. 2000; Stavrides 2006). 
Our results provide evidence that Cd alters 
AA carcinogen metabolism by interfering with 
the NAT­dependent acetylation pathway. This 
may represent an additional mechanism con­
tributing to Cd carcinogenesis.
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